<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04773327</url>
  </required_header>
  <id_info>
    <org_study_id>MA-GynC-II-001</org_study_id>
    <nct_id>NCT04773327</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies</brief_title>
  <official_title>A Multicenter, Randomized Controlled, Open Clinical Study of the Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemotherapy in Patients With Gynecological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiaohua Wu MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multi-center, forward-looking, open, randomized, controlled clinical trial.&#xD;
      This study aims to analyze the effects of Mecapegfilgrastim Injection prevention versus&#xD;
      non-prevention for neutropenia in ovarian cancer, cervical cancer, endometrial cancer&#xD;
      patients after chemical therapy.&#xD;
&#xD;
      Patients are randomized into study group and control group. All patients receive PTX+platinum&#xD;
      chemotherapy of 3 weeks. In study group, patients accept PEG-rhG-CSF 24-48 hours from the&#xD;
      chemotherapy. While the control group patients are only observed closely. Patient receive&#xD;
      three courses of treatment.&#xD;
&#xD;
      The primary end is the incidence of 3/4 level neutropenia in three courses of chemotherapy.&#xD;
&#xD;
      The secondary ends include: the incidences and duration of neutropenia in every course of&#xD;
      chemotherapy, the incidences of FN in three courses and every course of chemotherapy, the&#xD;
      incidences of infection in three courses and every course of chemotherapy, the delay time of&#xD;
      the next cycle of chemotherapy due to FN or infection, the RDI of the second and third cycles&#xD;
      of chemotherapy, adverse events related to G-CSF, quality of life, cost of medicine and&#xD;
      admitting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of third/fourth level neutropenia</measure>
    <time_frame>three months</time_frame>
    <description>Incidence of third/fourth level neutropenia during three cycles chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>three months</time_frame>
    <description>Incidence of febrile neutropenia during every cycle chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The duration time of third/fourth level neutropenia</measure>
    <time_frame>three months</time_frame>
    <description>The duration time of third/fourth level neutropenia during three cycles chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infection</measure>
    <time_frame>three months</time_frame>
    <description>Incidence of third/fourth level neutropenia during three cycles chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delay time of chemotherapy</measure>
    <time_frame>three months</time_frame>
    <description>The delay time of the next cycle of chemotherapy due to FN or infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of chemotherapy</measure>
    <time_frame>three months</time_frame>
    <description>Relative dose intensity of the second and third chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>three months</time_frame>
    <description>Incidence of adverse events related to granulocyte colony stimulating factor according to common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gynecologic Malignant Tumor</condition>
  <arm_group>
    <arm_group_label>PEG-rhG-CSF prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mecapegfilgrastim subcutaneous injection, 6mg, 24-48h after the end of antitumor drug administration in each chemotherapy cycle,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-prevention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Only close monitoring after chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mecapegfilgrastim Injection</intervention_name>
    <description>24-48h after the end of antitumor drug administration in each chemotherapy cycle, Mecapegfilgrastim was injected subcutaneously, 6mg/ time, once/cycle</description>
    <arm_group_label>PEG-rhG-CSF prevention</arm_group_label>
    <other_name>PEG- rhg - csf</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages 18-70&#xD;
&#xD;
          -  Weight ≥45 kg&#xD;
&#xD;
          -  ≤2 lines chemotherapy or postoperative adjuvant chemotherapy patients with cervical&#xD;
             cancer, ovarian cancer and endometrial cancer&#xD;
&#xD;
          -  Receive paclitaxel combined with platinum three weeks per cycle of chemotherapy&#xD;
&#xD;
          -  With an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1&#xD;
&#xD;
          -  Expected survival time of &gt; 3 months&#xD;
&#xD;
          -  Main organ functions meet the following criteria:&#xD;
&#xD;
               1. Hb≥75g/L; WBC≥3.0×109/L; ANC≥1.5×109/L; PLT≥80×109/L;&#xD;
&#xD;
               2. APTT-ULN≤10s; PT-ULN≤3s; TT-ULN≤3s;&#xD;
&#xD;
               3. ALT≤2.5×ULN; AST≤2.5×ULN; TBIL≤2.5×ULN;&#xD;
&#xD;
               4. BUN≤1.5×ULN; Cr≤1.5×ULN; UA≤1.5×ULN；Creatinine clearance≥40mL/min;&#xD;
&#xD;
               5. without obvious cardiac dysfunction&#xD;
&#xD;
          -  Provided consent for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With uncontrollable infections or receive systemic antibiotics within 72 hours prior&#xD;
             to chemotherapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Received bone marrow or hematopoietic stem cell transplantation within the past 3&#xD;
             months&#xD;
&#xD;
          -  Concurrent chemoradiotherapy&#xD;
&#xD;
          -  Presence of hematological disorders: systemic lupus erythematosus, sjogren's syndrome,&#xD;
             rheumatic autoimmune disease, mixed and hoof tissue disease, autoimmune hemolytic&#xD;
             anemia, leukopenia , chronic granulocyte leukemia, bone marrow dysplasia syndrome,&#xD;
             aplastic anemia, congenital and idiopathic neutropenia, myelodysplastic syndrome,&#xD;
             cyclic neutropenia, primary and secondary thrombocytopenic purpura, etc&#xD;
&#xD;
          -  Presence of risk of thrombus or high risk of clotting&#xD;
&#xD;
          -  Presence of psychosis, neurological disease or brain metastases from tumors&#xD;
&#xD;
          -  Presence of uncontrollable complicated disease including symptomatic congestive heart&#xD;
             failure, uncontrollable hypertension, unstable angina pectoris, active peptic ulcer,&#xD;
             or hemorrhagic disease&#xD;
&#xD;
          -  Presence of uncontrollable infectious diseases, active viral hepatitis, tuberculosis,&#xD;
             HIV&#xD;
&#xD;
          -  Allergic to recombinant human granulocyte stimulating factor or other biological&#xD;
             products of E. coli origin&#xD;
&#xD;
          -  Received clinical trials within 1 month prior to enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaohua Wu, MD&amp;PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>director of gynecologic oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lingfang Xia, M.D.</last_name>
    <phone>13774211977</phone>
    <email>nightxlf@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaohua Wu, MD&amp;PHD</last_name>
    <phone>+862164175590</phone>
    <email>alizheng@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>No. 270, Dongan Road, Xuhui District, Shanghai, China</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaohua Wu</last_name>
      <phone>+862164175590</phone>
      <email>alizheng@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaohua Wu MD</investigator_full_name>
    <investigator_title>director of gynecologic oncology</investigator_title>
  </responsible_party>
  <keyword>neutropenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data is available per require after approved by ethics broad</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

